Avera Cancer Institute

Clinical research site in Sioux Falls, South Dakota

Part of Avera Cancer Institute

As of July 2026, 42 paid clinical trials are recruiting at Avera Cancer Institute in Sioux Falls, South Dakota. Active studies at this site cover conditions such as Breast Cancer, Endometrial Cancer and Ovarian Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Avera Cancer Institute (42)

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

for CRC (Colorectal Cancer)

67 locations incl. Tucson

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT07284849·Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

for Intestinal Neoplasms

166 locations incl. Chandler

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07222800·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

for Pancreatic Cancer

29 locations incl. Los Angeles

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT07252232·Phase 3·Recruiting·Listed Nov 2025

Apply to this trial

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for Breast Cancer

169 locations incl. Daphne

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06492616·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

for Triple Negative Breast Cancer

124 locations incl. Birmingham

Sponsor: Gilead Sciences

Sex: All·Age: 18+

Code: NCT05633654·Phase 3·Recruiting·Listed Dec 2022

Apply to this trial

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

for Colorectal Neoplasms

104 locations incl. Glendale

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT05253651·Phase 3·Recruiting·Listed Feb 2022

Apply to this trial

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

for Advanced Non-Small Cell Lung Cancer

192 locations incl. Goodyear

Sponsor: Mirati Therapeutics Inc.

Sex: All·Age: 18+

Code: NCT04613596·Phase 2, Phase 3·Recruiting·Listed Nov 2020

Apply to this trial

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

for PIK3CA Mutation

52 locations incl. Gilbert

Sponsor: Relay Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06982521·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

54 locations incl. Daphne

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06065748·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

for NSCLC (Non-small Cell Lung Cancer)

43 locations incl. Birmingham

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT06881784·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

for Large B-cell Lymphoma

60 locations incl. Gilbert

Sponsor: Allogene Therapeutics

Sex: All·Age: 18+

Code: NCT06500273·Phase 2·Recruiting·Listed Jul 2024

Apply to this trial

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

for Metastatic Breast Cancer

26 locations incl. Cerritos

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06324357·Phase 1, Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

for Triple Negative Breast Cancer

26 locations incl. Phoenix

Sponsor: Day One Biopharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT05377996·Phase 1, Phase 2·Recruiting·Listed May 2022

Apply to this trial

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

for Melanoma, Cutaneous Malignant

37 locations incl. Phoenix

Sponsor: Immatics US, Inc.

Sex: All·Age: 18+

Code: NCT06743126·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

for Breast Cancer

53 locations incl. Anchorage

Sponsor: Exact Sciences Corporation

Sex: All·Age: 18+

Code: NCT06401421·Recruiting·Listed May 2024

Apply to this trial

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

for Chronic Graft-Versus-Host Disease (cGVHD)

26 locations incl. Duarte

Sponsor: Deciphera Pharmaceuticals, LLC

Sex: All·Age: 18+

Code: NCT06619561·Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

for Extensive Stage Small Cell Lung Cancer

13 locations incl. Gilbert

Sponsor: Amgen

Sex: All·Age: 18 - 90

Code: NCT07037758·Phase 1·Recruiting·Listed Jun 2025

Apply to this trial

A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

for Ovarian Cancer

13 locations incl. Augusta

Sponsor: Compugen Ltd

Sex: Female·Age: 18+

Code: NCT06888921·Phase 1, Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

for Endometrial Cancer

18 locations incl. La Jolla

Sponsor: Faeth Therapeutics

Sex: Female·Age: 18+

Code: NCT06463028·Phase 2·Recruiting·Listed Jun 2024

Apply to this trial

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

for Advanced Microsatellite Stable Colorectal Cancer

4 locations incl. North Haven

Sponsor: Gilead Sciences

Sex: All·Age: 18+

Code: NCT07527858·Phase 2·Recruiting·Listed Apr 2026

Apply to this trial

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

for Breast Cancer

6 locations incl. Marshall

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT07405801·Phase 2·Recruiting·Listed Feb 2026

Apply to this trial

A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors

for Advanced Solid Tumor

5 locations incl. Celebration

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT06803680·Phase 1·Recruiting·Listed Jan 2025

Apply to this trial

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

for Extensive Stage Small Cell Lung Cancer

6 locations incl. Los Angeles

Sponsor: Amgen

Sex: All·Age: 18+

Code: NCT06598306·Phase 1·Recruiting·Listed Sep 2024

Apply to this trial

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

for Recurrent Head and Neck Squamous Cell Carcinoma

7 locations incl. Duarte

Sponsor: Rakuten Medical, Inc.

Sex: All·Age: 18+

Code: NCT06699212·Phase 3·Recruiting·Listed Nov 2024

Apply to this trial

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

for Breast Cancer

1105 locations incl. Anchorage

Sponsor: NRG Oncology

Sex: Female·Age: 18 - 60

Code: NCT05879926·Phase 3·Recruiting·Listed May 2023

Apply to this trial

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

for Stage III Colon Cancer

922 locations incl. Fairhope

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05174169·Phase 2, Phase 3·Recruiting·Listed Dec 2021

Apply to this trial

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

for Locally Advanced Cervical Adenocarcinoma

289 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT07061977·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

for Anatomic Stage II Breast Cancer AJCC v8

776 locations incl. Fairhope

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05812807·Phase 3·Recruiting·Listed Apr 2023

Apply to this trial

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

for Advanced Esophageal Adenocarcinoma

643 locations incl. Anchorage

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05677490·Phase 3·Recruiting·Listed Jan 2023

Apply to this trial

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

for Head and Neck Squamous Cell Carcinoma

466 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT02734537·Phase 2·Recruiting·Listed Apr 2016

Apply to this trial

Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects

for Malignancy

405 locations incl. Anchorage

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: All ages

Code: NCT04242095·Recruiting·Listed Jan 2020

Apply to this trial

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

for Extensive Stage Lung Small Cell Carcinoma

273 locations incl. Anchorage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04402788·Phase 2, Phase 3·Recruiting·Listed May 2020

Apply to this trial

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

for Pancreatic Acinar Cell Carcinoma

261 locations incl. Kingman

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04858334·Phase 2·Recruiting·Listed Apr 2021

Apply to this trial

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

for Plasma Cell Myeloma

389 locations incl. Anchorage

Sponsor: SWOG Cancer Research Network

Sex: All·Age: All ages

Code: NCT05561387·Phase 3·Recruiting·Listed Sep 2022

Apply to this trial

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

for Locally Advanced Urothelial Carcinoma

150 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06524544·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

for Metastatic Head and Neck Squamous Cell Carcinoma

170 locations incl. Little Rock

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06589804·Phase 3·Recruiting·Listed Sep 2024

Apply to this trial

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

for Recurrent Head and Neck Squamous Cell Carcinoma

130 locations incl. Little Rock

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 79

Code: NCT04671667·Phase 2·Recruiting·Listed Dec 2020

Apply to this trial

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

for Buccal Mucosa Squamous Cell Carcinoma

87 locations incl. Gilbert

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT04333537·Phase 2, Phase 3·Recruiting·Listed Apr 2020

Apply to this trial

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

for Fallopian Tube Endometrioid Adenocarcinoma

645 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06580314·Phase 3·Recruiting·Listed Aug 2024

Apply to this trial

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

for Metastatic Lung Small Cell Carcinoma

148 locations incl. Anaheim

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT04804644·Phase 3·Recruiting·Listed Mar 2021

Apply to this trial

Showing the 40 most relevant of 42 recruiting trials at this site. Browse all with filters →

More research sites in Sioux Falls

Sanford USD Medical Center - Sioux Falls (90 trials)
Sanford Cancer Center Oncology Clinic (63 trials)
Sanford Health (15 trials)
Sanford Cancer Center (15 trials)
Circle Clinical Research (6 trials)
North Central Heart (6 trials)
Avera Cancer Institute- Research (5 trials)
Avera Research Institute (4 trials)
Avera Research Institute - Sioux Falls (4 trials)
Sanford USD Medical Center (4 trials)

Explore more

Paid clinical trials in Sioux Falls, SD · South Dakota clinical trials